Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jan;69(1):163–166. doi: 10.1038/bjc.1994.27

Combined evaluation of preoperative serum sialyl-Tn antigen and carcinoembryonic antigen levels is prognostic for gastric cancer patients.

I Takahashi 1, Y Maehara 1, T Kusumoto 1, S Kohnoe 1, Y Kakeji 1, H Baba 1, K Sugimachi 1
PMCID: PMC1968791  PMID: 8286201

Abstract

We have found that elevation of preoperative serum sialyl-Tn antigen (STN) levels is associated with a poor prognosis for gastric cancer patients, and these high levels remain in the advanced stage of the disease. We have now examined findings with the combined assay of STN and carcinoembryonic antigen (CEA) levels with regard to prediction of the prognosis of gastric cancer patients. Serum CEA levels and STN levels were determined preoperatively in 349 Japanese patients with gastric cancer. The patients were divided into four groups: (A) the CEA (-) STN (-) group (CEA < or = 5 ng ml-1, STN < or = 45 U ml-1, n = 286); (B) the CEA (-) STN (+) group (CEA < or = 5 ng ml-1, STN > 45 U ml-1, n = 31); (C) the CEA (+) STN (-) group (CEA > 5 ng ml-1, STN < or = 45 U ml-1, n = 17); and (D) the CEA (+) STN (+) group (CEA > 5 ng ml-1, STN > 45 U ml-1, n = 15). Clinicopathological features and the prognosis of these groups were examined. The distribution of two markers showed no significant correlation. The patients in the CEA (+) STN (+) group (group D) had more advanced disease than the patients in CEA (-) STN (-) group (group A); tumour size was larger, serosal invasion was prominent, lymphatic and vascular involvement was frequent and the tumour was more infiltrative. Lymph node metastasis and hepatic metastasis were more common. Total gastrectomy was usually performed, and the non-curative rate was higher. The 5-year survival of patients in the CEA (+) STN (+) (group D) was 14.5 +/- 9.5%, that is lower than that of patients in any other group [CEA (+) STN (-) (group C) 44.1 +/- 12.7% (P < 0.05); CEA (-) STN (+) (group B) 60.1 +/- 9.5% (P > 0.05); CEA (-) STN (-) (group A) 77.6 +/- 9.5% (P < 0.05)]. This combined assay of these markers will aid in estimating the prognosis and selecting appropriate drugs and care for gastric cancer patients.

Full text

PDF
163

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gold P., Freedman S. O. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965 Sep 1;122(3):467–481. doi: 10.1084/jem.122.3.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gunduz N., Fisher B., Saffer E. A. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979 Oct;39(10):3861–3865. [PubMed] [Google Scholar]
  3. Imura H., Mori T., Ohkura H., Ishii M., Ariyoshi H., Endo J., Kitao M., Takeda I., Kobayashi H., Inoue M. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl Tn antigen: (1). Evaluation of assay conditions and normal values. STN Study Group]. Gan To Kagaku Ryoho. 1989 Sep;16(9):3213–3219. [PubMed] [Google Scholar]
  4. Itzkowitz S. H., Bloom E. J., Kokal W. A., Modin G., Hakomori S., Kim Y. S. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer. 1990 Nov 1;66(9):1960–1966. doi: 10.1002/1097-0142(19901101)66:9<1960::aid-cncr2820660919>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  5. Itzkowitz S. H., Kim Y. S. New carbohydrate tumor markers. Gastroenterology. 1986 Feb;90(2):491–494. doi: 10.1016/0016-5085(86)90954-6. [DOI] [PubMed] [Google Scholar]
  6. Itzkowitz S. H., Yuan M., Montgomery C. K., Kjeldsen T., Takahashi H. K., Bigbee W. L., Kim Y. S. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989 Jan 1;49(1):197–204. [PubMed] [Google Scholar]
  7. Kano T., Koga T., Souda K., Abe Y., Yonemura T., Oka N., Inokuchi K. The usefulness of CEA as an indicator for early detection and a guide to the treatment of recurrent gastric cancer. Jpn J Surg. 1987 Jul;17(4):269–275. doi: 10.1007/BF02470699. [DOI] [PubMed] [Google Scholar]
  8. Kjeldsen T., Clausen H., Hirohashi S., Ogawa T., Iijima H., Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res. 1988 Apr 15;48(8):2214–2220. [PubMed] [Google Scholar]
  9. Koga T., Kano T., Souda K., Oka N., Inokuchi K. The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg. 1987 Sep;17(5):342–347. doi: 10.1007/BF02470632. [DOI] [PubMed] [Google Scholar]
  10. Maehara Y., Moriguchi S., Kakeji Y., Orita H., Haraguchi M., Korenaga D., Sugimachi K. Prognostic factors in adenocarcinoma in the upper one-third of the stomach. Surg Gynecol Obstet. 1991 Sep;173(3):223–226. [PubMed] [Google Scholar]
  11. Maehara Y., Moriguchi S., Yoshida M., Takahashi I., Korenaga D., Sugimachi K. Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer. 1991 Jun 15;67(12):3006–3009. doi: 10.1002/1097-0142(19910615)67:12<3006::aid-cncr2820671213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  12. Maehara Y., Sugimachi K., Akagi M., Kakegawa T., Shimazu H., Tomita M. Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res. 1990 Jul 1;50(13):3952–3955. [PubMed] [Google Scholar]
  13. Quentmeier A., Schlag P., Geisen H. P., Schmidt-Gayk H. Evaluation of Ca 12-5 as a tumor marker for gastric and colo-rectal cancer in comparison to CEA and Ca 19-9. Eur J Surg Oncol. 1987 Jun;13(3):197–201. [PubMed] [Google Scholar]
  14. Schabel F. M., Jr Concepts for systemic treatment of micrometastases. Cancer. 1975 Jan;35(1):15–24. doi: 10.1002/1097-0142(197501)35:1<15::aid-cncr2820350104>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  15. Shimizu N., Wakatsuki T., Murakami A., Yoshioka H., Hamazoe R., Kanayama H., Maeta M., Koga S. Carcinoembryonic antigen in gastric cancer patients. Oncology. 1987;44(4):240–244. doi: 10.1159/000226486. [DOI] [PubMed] [Google Scholar]
  16. Springer G. F. T and Tn, general carcinoma autoantigens. Science. 1984 Jun 15;224(4654):1198–1206. doi: 10.1126/science.6729450. [DOI] [PubMed] [Google Scholar]
  17. Takahashi I., Maehara Y., Kusumoto T., Yoshida M., Kakeji Y., Kusumoto H., Furusawa M., Sugimachi K. Predictive value of preoperative serum sialyl Tn antigen levels in prognosis of patients with gastric cancer. Cancer. 1993 Sep 15;72(6):1836–1840. doi: 10.1002/1097-0142(19930915)72:6<1836::aid-cncr2820720607>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  18. Tamada R., Hiramoto Y., Abe Y., Nouzuka T., Okamura T., Masuda H., Kano T., Kumashiro R., Inokuchi K. Serial determinations of carcinoembryonic antigen for early detection of recurrent gastric cancer. Jpn J Surg. 1982;12(6):429–433. doi: 10.1007/BF02469833. [DOI] [PubMed] [Google Scholar]
  19. Tamada R., Hiramoto Y., Tsujitani S., Nozuka T., Okamura T., Masuda H., Sugimachi K., Inokuchi K. Serum CEA levels facilitate detection of recurrences of cancer in patients after gastrectomy. Jpn J Surg. 1985 Jan;15(1):23–29. doi: 10.1007/BF02469853. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES